Back

Dong-A ST and Galux to develop new ADCs with AI antibody design

Verifying
  • Dong-A ST signed a joint research agreement with Galux to develop new ADCs.
  • Galux will use GaluxDesign to design ADC antibody candidates from scratch.
  • Dong-A ST subsidiary Aptis develops ADC drugs and platforms.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.